|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010583,
umls-concept:C0017262,
umls-concept:C0023636,
umls-concept:C0027651,
umls-concept:C0079613,
umls-concept:C0185117,
umls-concept:C0332120,
umls-concept:C0392756,
umls-concept:C1817907,
umls-concept:C1883720,
umls-concept:C2355612,
umls-concept:C2828008,
umls-concept:C2911684
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1988-12-22
|
|
pubmed:abstractText |
A cyclophosphamide (Cy)-resistant immunogenic tumour, the L5178Y lymphoma, was used to demonstrate that Cy-treatment of a host bearing this tumour enables passively transferred tumour-sensitized T cells to cause complete tumour regression without any need for Cy to cause a reduction in tumour burden. It was shown that whereas infusion of tumour-sensitized T cells from immune donors had very little effect on growth of the tumour, and whereas treatment with 150 mg/kg of Cy caused appreciable enhancement of tumour growth, combination therapy with Cy plus immune T cells caused complete tumour regression and resulted in long-term survival. Evidence that Cy treatment facilitated the expression of adoptive immunity against the L5178Y lymphoma by eliminating tumour-induced suppressor T cells consisted of the demonstration that tumour regression caused by combination treatment with Cy and immune T cells could be inhibited by infusing the recipient with Cy-sensitive, L3T4+ T cells from tumour-bearing but not from normal donors.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-1117258,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-2822805,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-2932519,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-2936064,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-2945892,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-299883,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-3155882,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-326003,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-3489291,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-4898911,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-6133894,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-6149246,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-6199292,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-6214496,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-6215457,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-6231095,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-6232335,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-6290658,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-6427998,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-6444236,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-6460831,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-6610533,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-6788892,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-6974214,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-7004136,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2972604-7004770
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0019-2805
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
65
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
87-92
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:2972604-Animals,
pubmed-meshheading:2972604-Combined Modality Therapy,
pubmed-meshheading:2972604-Cyclophosphamide,
pubmed-meshheading:2972604-Immunization, Passive,
pubmed-meshheading:2972604-Leukemia, Experimental,
pubmed-meshheading:2972604-Leukemia L5178,
pubmed-meshheading:2972604-Mice,
pubmed-meshheading:2972604-Mice, Inbred Strains,
pubmed-meshheading:2972604-T-Lymphocytes,
pubmed-meshheading:2972604-T-Lymphocytes, Regulatory,
pubmed-meshheading:2972604-Time Factors
|
|
pubmed:year |
1988
|
|
pubmed:articleTitle |
Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.
|
|
pubmed:affiliation |
Trudeau Institute, Inc., Saranac Lake, NY 12983.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
